Avenue Therapeutics to Participate in Upcoming Investor Conferences
Avenue Therapeutics (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in two upcoming investor conferences. Dr. Alexandra MacLean, the company's CEO, will represent Avenue at these events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, in New York, featuring a company presentation and one-on-one meetings.
2. Lake Street Capital Markets BIG8 Conference on September 12, 2024, in New York, offering one-on-one meetings.
The H.C. Wainwright presentation will be available for on-demand viewing by conference attendees starting September 9, 2024, at 7:00 a.m. ET. These conferences provide Avenue Therapeutics with opportunities to showcase their progress and engage with potential investors.
Avenue Therapeutics (Nasdaq: ATXI), una compagnia farmaceutica specializzata focalizzata sui trattamenti per le malattie neurologiche, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. Dr. Alexandra MacLean, CEO dell'azienda, rappresenterà Avenue in questi eventi:
1. H.C. Wainwright 26a Conferenza Globale Annuale sugli Investimenti il 9 settembre 2024, a New York, con una presentazione dell'azienda e incontri individuali.
2. Lake Street Capital Markets BIG8 Conference il 12 settembre 2024, a New York, offrendo incontri individuali.
La presentazione di H.C. Wainwright sarà disponibile per la visione on-demand da parte dei partecipanti alla conferenza a partire dal 9 settembre 2024, alle 7:00 ET. Queste conferenze offrono ad Avenue Therapeutics opportunità per mostrare i loro progressi e interagire con potenziali investitori.
Avenue Therapeutics (Nasdaq: ATXI), una compañía farmacéutica especializada en tratamientos para enfermedades neurológicas, ha anunciado su participación en dos próximas conferencias para inversores. Dr. Alexandra MacLean, CEO de la compañía, representará a Avenue en estos eventos:
1. H.C. Wainwright 26ª Conferencia Anual Global de Inversión el 9 de septiembre de 2024, en Nueva York, con una presentación de la empresa y reuniones uno a uno.
2. Lake Street Capital Markets BIG8 Conference el 12 de septiembre de 2024, en Nueva York, ofreciendo reuniones uno a uno.
La presentación de H.C. Wainwright estará disponible para visualización on-demand por parte de los asistentes a la conferencia a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET. Estas conferencias brindan a Avenue Therapeutics oportunidades para mostrar sus avances e interactuar con posibles inversores.
아베뉴 테라퓨틱스(Avenue Therapeutics, Nasdaq: ATXI), 신경계 질환 치료에 중점을 둔 전문 제약 회사가 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 회사의 CEO인 Dr. Alexandra MacLean이 이 행사에서 아베뉴를 대표할 것입니다:
1. H.C. Wainwright 제26회 연례 글로벌 투자 회의가 2024년 9월 9일 뉴욕에서 열리며, 회사 발표 및 개별 미팅이 포함됩니다.
2. Lake Street Capital Markets BIG8 회의가 2024년 9월 12일 뉴욕에서 열리며, 개별 미팅이 제공됩니다.
H.C. Wainwright 발표는 2024년 9월 9일 오전 7:00 ET부터 회의 참석자들이 시청할 수 있습니다. 이러한 회의는 아베뉴 테라퓨틱스가 그들의 발전을 선보이고 잠재적 투자자와 소통할 수 있는 기회를 제공합니다.
Avenue Therapeutics (Nasdaq: ATXI), une entreprise pharmaceutique spécialisée dans les traitements des maladies neurologiques, a annoncé sa participation à deux prochaines conférences pour investisseurs. Dr. Alexandra MacLean, la PDG de la société, représentera Avenue lors de ces événements :
1. H.C. Wainwright 26ème Conférence Annuelle Mondiale des Investissements le 9 septembre 2024 à New York, avec une présentation de la société et des réunions individuelles.
2. Lake Street Capital Markets BIG8 Conférence le 12 septembre 2024 à New York, offrant des réunions individuelles.
La présentation de H.C. Wainwright sera disponible en visionnage à la demande pour les participants à la conférence à partir du 9 septembre 2024 à 7h00 ET. Ces conférences offrent à Avenue Therapeutics des opportunités de présenter leurs avancées et d'interagir avec des investisseurs potentiels.
Avenue Therapeutics (Nasdaq: ATXI), ein auf neurologische Erkrankungen spezialisiertes Pharmaunternehmen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Dr. Alexandra MacLean, die CEO des Unternehmens, wird Avenue bei diesen Veranstaltungen vertreten:
1. H.C. Wainwright 26. jährliche globale Investorenkonferenz am 9. September 2024 in New York, mit einer Unternehmenspräsentation und Einzelgesprächen.
2. Lake Street Capital Markets BIG8 Konferenz am 12. September 2024 in New York, die Einzelgespräche anbietet.
Die Präsentation von H.C. Wainwright wird den Konferenzteilnehmenden ab dem 9. September 2024 um 7:00 Uhr ET zur On-Demand-Anzeige zur Verfügung stehen. Diese Konferenzen bieten Avenue Therapeutics die Möglichkeit, ihre Fortschritte zu präsentieren und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences:
H.C. Wainwright 26th Annual Global Investment Conference
Date: Monday, September 9, 2024
Location: New York
Format: Company Presentation and 1x1 Meetings
Lake Street Capital Markets BIG8 Conference
Date: Thursday, September 12, 2024
Location: New York
Format: 1x1 Meetings
The H.C. Wainwright company presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.
Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com
FAQ
When is Avenue Therapeutics (ATXI) participating in the H.C. Wainwright Global Investment Conference?
What is the format of Avenue Therapeutics' (ATXI) participation in the Lake Street Capital Markets BIG8 Conference?
Who will represent Avenue Therapeutics (ATXI) at the upcoming investor conferences?
When will the H.C. Wainwright conference presentation by Avenue Therapeutics (ATXI) be available for viewing?
